



Targeted PSMA Radionuclide Drug Conjugates Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-28	122	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Targeted PSMA Radionuclide Drug Conjugates market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Targeted PSMA Radionuclide Drug Conjugates is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Targeted PSMA Radionuclide Drug Conjugates is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Targeted PSMA Radionuclide Drug Conjugates include Grand Pharmaceutical, Novartis, University of California, Telix Pharmaceutical and Lantheus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Targeted PSMA Radionuclide Drug Conjugates market in terms of revenue (US\$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Targeted PSMA Radionuclide Drug Conjugates Market by Company

Grand Pharmaceutical

Novartis

University of California

Telix Pharmaceutical

Lantheus

Targeted PSMA Radionuclide Drug Conjugates Segment by Type

Diagnostic

Therapeutic

Targeted PSMA Radionuclide Drug Conjugates Segment by Application

Hospital

Specialist Clinic

Other

Targeted PSMA Radionuclide Drug Conjugates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks

on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted PSMA Radionuclide Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted PSMA Radionuclide Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted PSMA Radionuclide Drug Conjugates.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Targeted PSMA Radionuclide Drug Conjugates manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Targeted PSMA Radionuclide Drug Conjugates by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Targeted PSMA Radionuclide Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size (2021-2032)
 - 2.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales (2021-2032)
 - 2.2.3 Global Targeted PSMA Radionuclide Drug Conjugates Market Average Price (2021-2032)
- 2.3 Targeted PSMA Radionuclide Drug Conjugates by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Diagnostic
 - 2.3.3 Therapeutic
- 2.4 Targeted PSMA Radionuclide Drug Conjugates by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Hospital
 - 2.4.3 Specialist Clinic
 - 2.4.4 Other

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Targeted PSMA Radionuclide Drug Conjugates Revenue of Manufacturers (2021-2026)
- 3.4 Global Targeted PSMA Radionuclide Drug Conjugates Average Price by Manufacturers (2021-2026)
- 3.5 Global Targeted PSMA Radionuclide Drug Conjugates Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Targeted PSMA Radionuclide Drug Conjugates, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Targeted PSMA Radionuclide Drug Conjugates, Product Type & Application
- 3.8 Global Manufacturers of Targeted PSMA Radionuclide Drug Conjugates, Established Date
- 3.9 Global Targeted PSMA Radionuclide Drug Conjugates Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Grand Pharmaceutical
 - 4.1.1 Grand Pharmaceutical Company Information
 - 4.1.2 Grand Pharmaceutical Business Overview
 - 4.1.3 Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
 - 4.1.5 Grand Pharmaceutical Recent Developments
- 4.2 Novartis

- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 University of California
 - 4.3.1 University of California Company Information
 - 4.3.2 University of California Business Overview
 - 4.3.3 University of California Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 University of California Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
 - 4.3.5 University of California Recent Developments
- 4.4 Telix Pharmaceutical
 - 4.4.1 Telix Pharmaceutical Company Information
 - 4.4.2 Telix Pharmaceutical Business Overview
 - 4.4.3 Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
 - 4.4.5 Telix Pharmaceutical Recent Developments
- 4.5 Lantheus
 - 4.5.1 Lantheus Company Information
 - 4.5.2 Lantheus Business Overview
 - 4.5.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
 - 4.5.5 Lantheus Recent Developments

5 Global Targeted PSMA Radionuclide Drug Conjugates Market Scenario by Region

- 5.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2021-2032
 - 5.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2021-2026
 - 5.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2027-2032
- 5.3 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Region: 2021-2032
 - 5.3.1 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Region: 2021-2026
 - 5.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Region: 2027-2032
- 5.4 North America Targeted PSMA Radionuclide Drug Conjugates Market Facts & Figures by Country
 - 5.4.1 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2032)
 - 5.4.3 North America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Targeted PSMA Radionuclide Drug Conjugates Market Facts & Figures by Country
 - 5.5.1 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2032)
 - 5.5.3 Europe Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia

- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland

5.6 Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Market Facts & Figures by Country

- 5.6.1 Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia

5.7 South America Targeted PSMA Radionuclide Drug Conjugates Market Facts & Figures by Country

- 5.7.1 South America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2032)
- 5.7.3 South America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile

5.8 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Facts & Figures by Country

- 5.8.1 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries

6 Segment by Type

6.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2032)

- 6.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Type (2021-2032)

6.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Type (2021-2032)

- 6.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2032) & (US\$ Million)
- 6.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Type (2021-2032)

6.3 Global Targeted PSMA Radionuclide Drug Conjugates Price by Type (2021-2032)

7 Segment by Application

7.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2032)

- 7.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Application (2021-2032)

7.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Application (2021-2032)

- 7.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Application (2021-2032)

7.3 Global Targeted PSMA Radionuclide Drug Conjugates Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Targeted PSMA Radionuclide Drug Conjugates Value Chain Analysis

8.1.1 Targeted PSMA Radionuclide Drug Conjugates Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Targeted PSMA Radionuclide Drug Conjugates Production Mode & Process

8.2 Targeted PSMA Radionuclide Drug Conjugates Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Targeted PSMA Radionuclide Drug Conjugates Distributors

8.2.3 Targeted PSMA Radionuclide Drug Conjugates Customers

9 Global Targeted PSMA Radionuclide Drug Conjugates Analyzing Market Dynamics

9.1 Targeted PSMA Radionuclide Drug Conjugates Industry Trends

9.2 Targeted PSMA Radionuclide Drug Conjugates Industry Drivers

9.3 Targeted PSMA Radionuclide Drug Conjugates Industry Opportunities and Challenges

9.4 Targeted PSMA Radionuclide Drug Conjugates Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Targeted PSMA Radionuclide Drug Conjugates Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Targeted PSMA Radionuclide Drug Conjugates Sales (K Units) of Manufacturers (2021-2026)
- Table 7: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Targeted PSMA Radionuclide Drug Conjugates Revenue of Manufacturers (2021-2026)
- Table 9: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Targeted PSMA Radionuclide Drug Conjugates Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Targeted PSMA Radionuclide Drug Conjugates Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Targeted PSMA Radionuclide Drug Conjugates, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Targeted PSMA Radionuclide Drug Conjugates, Product Type & Application
- Table 14: Global Targeted PSMA Radionuclide Drug Conjugates Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Targeted PSMA Radionuclide Drug Conjugates by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Grand Pharmaceutical Company Information
- Table 19: Grand Pharmaceutical Business Overview
- Table 20: Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
- Table 22: Grand Pharmaceutical Recent Developments
- Table 23: Novartis Company Information
- Table 24: Novartis Business Overview
- Table 25: Novartis Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Novartis Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
- Table 27: Novartis Recent Developments
- Table 28: University of California Company Information
- Table 29: University of California Business Overview
- Table 30: University of California Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: University of California Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
- Table 32: University of California Recent Developments
- Table 33: Telix Pharmaceutical Company Information
- Table 34: Telix Pharmaceutical Business Overview
- Table 35: Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
- Table 37: Telix Pharmaceutical Recent Developments
- Table 38: Lantheus Company Information
- Table 39: Lantheus Business Overview
- Table 40: Lantheus Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
- Table 42: Lantheus Recent Developments
- Table 43: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 44: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2021-2026) & (K Units)
- Table 45: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Region (2021-2026)
- Table 46: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2027-2032) & (K Units)
- Table 47: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Region (2027-2032)

- Table 48: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021-2026) & (US\$ Million)
- Table 49: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2026)
- Table 50: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2027-2032) & (US\$ Million)
- Table 51: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2027-2032)
- Table 52: North America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 53: North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units)
- Table 54: North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units)
- Table 55: North America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2026) & (US\$ Million)
- Table 56: North America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2027-2032) & (US\$ Million)
- Table 57: Europe Targeted PSMA Radionuclide Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 58: Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units)
- Table 59: Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units)
- Table 60: Europe Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2026) & (US\$ Million)
- Table 61: Europe Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2027-2032) & (US\$ Million)
- Table 62: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 63: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units)
- Table 64: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units)
- Table 65: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2026) & (US\$ Million)
- Table 66: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2027-2032) & (US\$ Million)
- Table 67: South America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: South America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units)
- Table 69: South America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units)
- Table 70: South America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: South America Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units)
- Table 74: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units)
- Table 75: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units)
- Table 78: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2027-2032) & (K Units)
- Table 79: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Type (2021-2026)
- Table 80: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Type (2027-2032)
- Table 81: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Type (2021-2026) & (US\$ Million)
- Table 82: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Type (2027-2032) & (US\$ Million)
- Table 83: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Type (2021-2026)
- Table 84: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Type (2027-2032)
- Table 85: Global Targeted PSMA Radionuclide Drug Conjugates Price by Type (2021-2026) & (US\$/Unit)
- Table 86: Global Targeted PSMA Radionuclide Drug Conjugates Price by Type (2027-2032) & (US\$/Unit)
- Table 87: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units)
- Table 88: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2027-2032) & (K Units)
- Table 89: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Application (2021-2026)
- Table 90: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Application (2027-2032)
- Table 91: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Application (2021-2026) & (US\$ Million)
- Table 92: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Application (2027-2032) & (US\$ Million)
- Table 93: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Application (2021-2026)
- Table 94: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Application (2027-2032)
- Table 95: Global Targeted PSMA Radionuclide Drug Conjugates Price by Application (2021-2026) & (US\$/Unit)
- Table 96: Global Targeted PSMA Radionuclide Drug Conjugates Price by Application (2027-2032) & (US\$/Unit)
- Table 97: Key Raw Materials
- Table 98: Raw Materials Key Suppliers
- Table 99: Targeted PSMA Radionuclide Drug Conjugates Distributors List
- Table 100: Targeted PSMA Radionuclide Drug Conjugates Customers List
- Table 101: Targeted PSMA Radionuclide Drug Conjugates Industry Trends
- Table 102: Targeted PSMA Radionuclide Drug Conjugates Industry Drivers
- Table 103: Targeted PSMA Radionuclide Drug Conjugates Industry Restraints
- Table 104: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Targeted PSMA Radionuclide Drug Conjugates Product Image
- Figure 5: Global Targeted PSMA Radionuclide Drug Conjugates Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Targeted PSMA Radionuclide Drug Conjugates Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Targeted PSMA Radionuclide Drug Conjugates Sales (2021-2032) & (K Units)
- Figure 8: Global Targeted PSMA Radionuclide Drug Conjugates Average Price (US\$/Unit) & (2021-2032)
- Figure 9: Diagnostic Product Image
- Figure 10: Therapeutic Product Image
- Figure 11: Hospital Product Image
- Figure 12: Specialist Clinic Product Image
- Figure 13: Other Product Image
- Figure 14: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Manufacturers in 2025
- Figure 15: Global Manufacturers of Targeted PSMA Radionuclide Drug Conjugates, Manufacturing Sites & Headquarters
- Figure 16: Global Top 5 and 10 Targeted PSMA Radionuclide Drug Conjugates Players Market Share by Revenue in 2025
- Figure 17: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 18: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 19: Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region in 2025
- Figure 20: Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Region in 2025
- Figure 21: North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country in 2025
- Figure 22: North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032)
- Figure 23: North America Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country (2021-2032)
- Figure 24: United States Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 25: Canada Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Mexico Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country in 2025
- Figure 28: Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032)
- Figure 29: Europe Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country (2021-2032)
- Figure 30: Germany Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: France Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: U.K. Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: Italy Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Russia Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Spain Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Switzerland Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Sweden Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Poland Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Country in 2025
- Figure 41: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032)
- Figure 42: Asia Pacific Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country (2021-2032)
- Figure 43: China Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Japan Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: South Korea Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: India Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: Australia Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Taiwan Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: South America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country in 2025
- Figure 52: South America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032)
- Figure 53: South America Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country (2021-2032)
- Figure 54: Brazil Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: Argentina Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Chile Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country in 2025
- Figure 58: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032)
- Figure 59: Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country (2021-2032)
- Figure 60: Egypt Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: South Africa Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 62: Israel Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: Türkiye Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: GCC Countries Targeted PSMA Radionuclide Drug Conjugates Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Type (2021-2032)
- Figure 66: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Type (2021-2032)
- Figure 67: Global Targeted PSMA Radionuclide Drug Conjugates Price (US\$/Unit) by Type (2021-2032)
- Figure 68: Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Application (2021-2032)
- Figure 69: Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Application (2021-2032)
- Figure 70: Global Targeted PSMA Radionuclide Drug Conjugates Price (US\$/Unit) by Application (2021-2032)
- Figure 71: Targeted PSMA Radionuclide Drug Conjugates Value Chain
- Figure 72: Targeted PSMA Radionuclide Drug Conjugates Production Mode & Process
- Figure 73: Direct Comparison with Distribution Share
- Figure 74: Distributors Profiles
- Figure 75: Targeted PSMA Radionuclide Drug Conjugates Industry Opportunities and Challenges